ecancer

The Oncopolicy Roundtable: ECCO's President and special guests highlight key issues

ECCO 15 - ESMO 34

22 Jul 2009

Standard treatment plus trastuzumab for HER2+ gastric cancer

Dr Eric Van Cutsem - University Hospital Gasthuisberg, Belgium

3 Jul 2009

ASCO: Prophylactic creams and antibiotics reduce severe drug-related skin rash

Dr. Edith Mitchell, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

22 Jun 2009

ASCO: Oxaliplatin does not improve outcomes for rectal cancer

Dr. Carlo Aschele - E.O. Ospedali Galliera, Italy

18 Jun 2009

ASCO: Trial compares common adjuvant treatments for pancreatic cancer

Dr. John Neoptolemos - University of Liverpool, Liverpool, UK

18 Jun 2009

ASCO: Surgery unnecessary for majority of patients with advanced colorectal cancer

Dr. Philip B. Paty - Memorial Sloan-Kettering Cancer Center, New York, USA

18 Jun 2009

ASCO: Bevacizumab and standard adjuvant chemotherapy: no improvement in disease-free survival for early-stage colon cancer

Dr Norman Wolmark - Chairman Dept of Human Oncology, Allegheny General Hospital, US

17 Jun 2009

AACR 2009: Common genetic variations and predisposition to cancer

Prof Bruce Ponder - Cancer Research UK, Cambridge Institute

14 May 2009

AACR 2009: 100 years of AACR

Dr Margaret Foti - CEO of the American Association for Cancer Research

14 May 2009

AACR 2009: Anti-angiogenics to tackle brain and prostate tumours

Prof Gabriele Bergers - University of California, San Francisco

14 May 2009

AACR 2009: Determinants of screening colonoscopy among african-american older adults

Prof Jean Ford - Dept of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, USA

7 May 2009

AACR 2009: Genetic influences in response to EGFR for metastatic colorectal cancer

Frederica Di Nicolantonio - Laboratory of Molecular Genetics, Institute for Cancer Research and Treatment, University of Turin Medical School, Italy

1 May 2009

More from ecancer